Otis Brawley, chief medical officer of the American Cancer Society, was quoted as saying, “We desperately need to figure out a way to predict the folks who are going to respond to the drug versus the folks who will only get side effects of the drug.” This seems precisely what the vintafolide and etarfolatide combination is able to do: identify the patients most likely to respond and then provide a drug specifically targeted for them.
Wish I had sold some on the run higher and used the cash to buy back at these lower prices. GLTA
"In addition, the DSMB recommended investigators and patients be advised that vintafolide monotherapy is not likely to be declared superior to docetaxel in progression-free survival or PFS at the end of the study, and patients currently on vintafolide monotherapy may continue treatment based on guidance from their investigator."
By not d/c the monotherapy as futile I'm guessing they see results similar to docetaxel. DSMB wouldn't want to put patients through needless side effects if no benefit. I'm seeing this as an unexpected plus